Interleukin-1 (IL-1) production in a mouse tissue chamber model of inflammation. II. Identification of (tissue) macrophages as the IL-1 producing cells and the effect of anti-inflammatory drugs - PubMed (original) (raw)

. 1993 Mar;38(3-4):255-64.

doi: 10.1007/BF01976218.

Affiliations

• PMID: 8213352
• DOI: 10.1007/BF01976218

Interleukin-1 (IL-1) production in a mouse tissue chamber model of inflammation. II. Identification of (tissue) macrophages as the IL-1 producing cells and the effect of anti-inflammatory drugs

J Dawson et al. Agents Actions. 1993 Mar.

Abstract

We have used our newly described mouse tissue chamber model [1], to investigate the process of IL-1 production in more detail. The inflammatory reaction in the tissue surrounding the implanted chambers was investigated histologically and by using the polymerase chain reaction (PCR). The inflammatory response included influx of leucocytes into the granuloma surrounding the tissue chamber, expression of IL-1 beta on macrophages present in the inflamed tissue and an increase in the mRNA coding for IL-1 beta and IL-6 proteins in the granuloma. The effects of three anti-inflammatory or immunosuppressive drugs, prednisolone, indomethacin and cyclosporin A, on IL-1 beta and PGE2 production in zymosan and Bordetella-pertussis-vaccine (BPV)-challenged tissue chambers were also examined. Oral treatment with prednisolone and cyclosporin A of zymosan-challenged animals showed a dose-dependent reduction of IL-1 beta concentrations, but no effect of indomethacin. Both prednisolone and indomethacin dose-dependently reduced PGE2 concentrations to control levels, while cyclosporin A was effective only at the highest dose tested (100 mg/kg/day p.o.). In drug-treated BPV-challenged animals, prednisolone and cyclosporin A also showed a dose-dependent reduction of IL-1 beta, while indomethacin was again ineffective. Prednisolone and indomethacin also dose-dependently reduced the PGE2 concentrations to control levels, whereas cyclosporin A was effective only at the highest dose tested (100 mg/kg/day p.o.). This model will be useful for investigating the mechanisms controlling the production of IL-1 beta from the mRNA level to the secretion of mature biologically active protein [1], and in the search for new drugs which could selectively interfere with this process.

PubMed Disclaimer

Similar articles

• Differential effects of prednisolone and indomethacin on zymosan-induced inflammation in a modified murine tissue-chamber model.
  Oluyomi AO, Nguyen H, Towbin H, Dawson J, Vosbeck K. Oluyomi AO, et al. Inflamm Res. 1995 Aug;44(8):350-6. doi: 10.1007/BF01796267. Inflamm Res. 1995. PMID: 8581523
• Interleukin-1 (IL-1) production in a mouse tissue chamber model of inflammation. I. Development and initial characterisation of the model.
  Dawson J, Rordorf-Adam C, Geiger T, Towbin H, Kunz S, Nguyen H, Zingel O, Chaplin D, Vosbeck K. Dawson J, et al. Agents Actions. 1993 Mar;38(3-4):247-54. doi: 10.1007/BF01976217. Agents Actions. 1993. PMID: 8213351
• In vitro and in vivo therapeutics of β-thujaplicin on LPS-induced inflammation in macrophages and septic shock in mice.
  Shih MF, Chen LY, Tsai PJ, Cherng JY. Shih MF, et al. Int J Immunopathol Pharmacol. 2012 Jan-Mar;25(1):39-48. doi: 10.1177/039463201202500106. Int J Immunopathol Pharmacol. 2012. PMID: 22507316

Cited by

• Measurement of interleukin-1 liberation in zymosan air-pouch exudate in mice.
  Erdö F, Török K, Székely JI. Erdö F, et al. Agents Actions. 1994 Mar;41(1-2):93-5. doi: 10.1007/BF01986403. Agents Actions. 1994. PMID: 8079830
• Differential effects of prednisolone and indomethacin on zymosan-induced inflammation in a modified murine tissue-chamber model.
  Oluyomi AO, Nguyen H, Towbin H, Dawson J, Vosbeck K. Oluyomi AO, et al. Inflamm Res. 1995 Aug;44(8):350-6. doi: 10.1007/BF01796267. Inflamm Res. 1995. PMID: 8581523
• Secreted Gaussia princeps luciferase as a reporter of Escherichia coli replication in a mouse tissue cage model of infection.
  Liu M, Blinn C, McLeod SM, Wiseman JW, Newman JV, Fisher SL, Walkup GK. Liu M, et al. PLoS One. 2014 Mar 4;9(3):e90382. doi: 10.1371/journal.pone.0090382. eCollection 2014. PLoS One. 2014. PMID: 24595353 Free PMC article.
• Contribution of interleukin-1 beta to the inflammation-induced increase in nerve growth factor levels and inflammatory hyperalgesia.
  Safieh-Garabedian B, Poole S, Allchorne A, Winter J, Woolf CJ. Safieh-Garabedian B, et al. Br J Pharmacol. 1995 Aug;115(7):1265-75. doi: 10.1111/j.1476-5381.1995.tb15035.x. Br J Pharmacol. 1995. PMID: 7582555 Free PMC article.
• Glucocorticoid-mediated enhancement of glutamatergic transmission may outweigh anti-inflammatory effects under conditions of neuropathic pain.
  Le Coz GM, Anton F, Hanesch U. Le Coz GM, et al. PLoS One. 2014 Mar 11;9(3):e91393. doi: 10.1371/journal.pone.0091393. eCollection 2014. PLoS One. 2014. PMID: 24618816 Free PMC article.

References

1. 1. Agents Actions. 1993 Mar;38(3-4):247-54 - PubMed
2. 1. Rheumatol Int. 1989;9(2):53-8 - PubMed
3. 1. Pharmacol Ther. 1983;21(3):389-428 - PubMed
4. 1. Eur J Immunol. 1990 Jan;20(1):163-70 - PubMed
5. 1. Nat New Biol. 1971 Jun 23;231(25):232-5 - PubMed

MeSH terms

Substances

LinkOut - more resources

• Research Materials

  • NCI CPTC Antibody Characterization Program